Related Experiment Video
Updated: Jun 4, 2026

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
Published on: March 14, 2025
Toxic epidermal necrolyis after vancomycin use: a case report and discussion of management
Avani Changela1, Hemangkumar Javaiya, Kiersten Rickenback
1Department of Internal Medicine, The Brooklyn Hospital Center, Brooklyn, NY 11201, USA. aachange@gmail.com
Abstract:
Vancomycin is a commonly used antibiotic for severe Gram-positive bacterial infections, especially for methicillin-resistant Staphylococcus Aureus and coagulase-negative staphylococci infections. Nevertheless, only few cases of toxic epidermal necrolysis have been reported since the introduction of Vancomycin into clinical practice. We report a case of a 35-year-old man who presented with multiple facial abscesses and methicillin-resistant Staphylococcus Aureus bactermia and who was started on Vancomycin and later developed toxic epidermal necrolysis.
Insights
Vancomycin is a critical antibiotic for severe bacterial infections. A rare case of toxic epidermal necrolysis developed in a patient treated with Vancomycin for methicillin-resistant Staphylococcus Aureus.
Area of Science:
- Pharmacology
- Dermatology
- Infectious Diseases
Background:
- Vancomycin is a glycopeptide antibiotic essential for treating severe Gram-positive bacterial infections.
- Methicillin-resistant Staphylococcus Aureus (MRSA) infections necessitate effective antibiotic options like Vancomycin.
- Adverse drug reactions to Vancomycin are uncommon, with toxic epidermal necrolysis being exceptionally rare.
Observation:
- A 35-year-old male presented with multiple facial abscesses and confirmed MRSA bacteremia.
- The patient was initiated on Vancomycin therapy for the severe staphylococcal infection.
- Following Vancomycin administration, the patient developed symptoms consistent with toxic epidermal necrolysis.
Findings:
- This case highlights a rare but severe adverse drug reaction to Vancomycin.
- The patient's presentation of toxic epidermal necrolysis occurred during treatment for MRSA bacteremia.
- The temporal relationship suggests Vancomycin as a potential causative agent for the observed dermatological emergency.
Implications:
- Clinicians should maintain a high index of suspicion for severe cutaneous adverse reactions, including toxic epidermal necrolysis, in patients receiving Vancomycin.
- Early recognition and prompt discontinuation of the suspected agent are crucial for managing toxic epidermal necrolysis.
- Further pharmacovigilance is warranted to better understand the risk factors and incidence of Vancomycin-induced toxic epidermal necrolysis.
Related Concept Videos
Drug Toxicity: Allergic Reactions
Clinical Significance of Antibiotic Resistance
Drug Toxicity: Overview
Endocarditis IV: Nursing Management
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Drug Toxicity: Risk factors